Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer.

Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK.

Urology. 2012 Dec;80(6):1236-42. doi: 10.1016/j.urology.2012.09.006.

2.

Managed care and the dissemination of robotic prostatectomy.

Zhang Y, Hollenbeck BK, Schroeck FR, Jacobs BL.

Surg Innov. 2014 Dec;21(6):566-71. doi: 10.1177/1553350614524841.

3.

Certificate of need regulations and the diffusion of intensity-modulated radiotherapy.

Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK.

Urology. 2012 Nov;80(5):1015-20. doi: 10.1016/j.urology.2012.07.042.

4.

The impact of technology diffusion on treatment for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK.

Med Care. 2013 Dec;51(12):1076-84. doi: 10.1097/MLR.0000000000000019.

5.

Certificate of need legislation and the dissemination of robotic surgery for prostate cancer.

Jacobs BL, Zhang Y, Skolarus TA, Wei JT, Montie JE, Schroeck FR, Hollenbeck BK.

J Urol. 2013 Jan;189(1):80-5. doi: 10.1016/j.juro.2012.08.185.

PMID:
23164388
6.

Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse.

Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK.

Health Aff (Millwood). 2012 Apr;31(4):750-9. doi: 10.1377/hlthaff.2011.1062.

7.

Technology diffusion and prostate cancer quality of care.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Zhang Y, Hollenbeck BK.

Urology. 2014 Nov;84(5):1066-72. doi: 10.1016/j.urology.2014.06.067.

8.

Cost implications of the rapid adoption of newer technologies for treating prostate cancer.

Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, Hu JC.

J Clin Oncol. 2011 Apr 20;29(12):1517-24. doi: 10.1200/JCO.2010.31.1217.

9.

Technology diffusion and diagnostic testing for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Weizer AZ, Montgomery JS, Wei JT, Shahinian VB, Hollenbeck BK.

J Urol. 2013 Nov;190(5):1715-20. doi: 10.1016/j.juro.2013.05.007.

10.

Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities.

Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD.

Lung Cancer. 2013 Nov;82(2):252-9. doi: 10.1016/j.lungcan.2013.08.015.

11.

Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.

Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP.

J Natl Cancer Inst. 2013 Jan 2;105(1):25-32. doi: 10.1093/jnci/djs463.

12.

Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study.

Gandaglia G, Karakiewicz PI, Briganti A, Trinh QD, Schiffmann J, Tian Z, Kim SP, Nguyen PL, Graefen M, Montorsi F, Sun M, Abdollah F.

Ann Oncol. 2014 May;25(5):979-86. doi: 10.1093/annonc/mdu087.

PMID:
24562445
13.

Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy.

Crandley EF, Hegarty SE, Hyslop T, Wilson DD, Dicker AP, Showalter TN.

Cancer Med. 2014 Apr;3(2):397-405. doi: 10.1002/cam4.205.

14.

Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy.

Goldin GH, Sheets NC, Meyer AM, Kuo TM, Wu Y, Stürmer T, Godley PA, Carpenter WR, Chen RC.

JAMA Intern Med. 2013 Jun 24;173(12):1136-43. doi: 10.1001/jamainternmed.2013.1020.

PMID:
23689844
15.

Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis.

Elkin EB, Ishill N, Riley GF, Bach PB, Gonen M, Begg CB, Schrag D.

J Natl Cancer Inst. 2008 Jul 16;100(14):1013-21. doi: 10.1093/jnci/djn208.

16.

Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.

Sher DJ, Neville BA, Chen AB, Schrag D.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e197-206. doi: 10.1016/j.ijrobp.2011.02.007.

PMID:
21596483
17.

Patterns of care and outcomes associated with intensity-modulated radiation therapy versus conventional radiation therapy for older patients with head-and-neck cancer.

Yu JB, Soulos PR, Sharma R, Makarov DV, Decker RH, Smith BD, Desai RA, Cramer LD, Gross CP.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e101-7. doi: 10.1016/j.ijrobp.2011.11.067.

PMID:
22342095
18.

Hospice use among Medicare managed care and fee-for-service patients dying with cancer.

McCarthy EP, Burns RB, Ngo-Metzger Q, Davis RB, Phillips RS.

JAMA. 2003 May 7;289(17):2238-45.

PMID:
12734135
19.

Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis.

Beadle BM, Liao KP, Elting LS, Buchholz TA, Ang KK, Garden AS, Guadagnolo BA.

Cancer. 2014 Mar 1;120(5):702-10. doi: 10.1002/cncr.28372. Erratum in: Cancer. 2014 Jun 1;120(11):1754.

20.

Certificate of need programs, intensity modulated radiation therapy use and the cost of prostate cancer care.

Khanna A, Hu JC, Gu X, Nguyen PL, Lipsitz S, Palapattu GS.

J Urol. 2013 Jan;189(1):75-9. doi: 10.1016/j.juro.2012.08.181.

PMID:
23164382
Items per page

Supplemental Content

Support Center